Astrazeneca Plc Stock Fundamentals
| ZEGA Stock | EUR 63.50 1.00 1.60% |
AstraZeneca PLC fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
AstraZeneca |
AstraZeneca PLC Company Shares Outstanding Analysis
AstraZeneca PLC's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current AstraZeneca PLC Shares Outstanding | 3.1 B |
Most of AstraZeneca PLC's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, AstraZeneca PLC has 3.1 B of shares currently outstending. This is much higher than that of the Healthcare sector and 143.89% higher than that of the Drug Manufacturers - Major industry. The shares outstanding for all Germany stocks is significantly lower than that of the firm.
AstraZeneca PLC Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 1.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.AstraZeneca Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.AstraZeneca PLC is currently under evaluation in shares outstanding category among its peers.
AstraZeneca Fundamentals
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0555 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 228.75 B | |||
| Shares Outstanding | 3.1 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 17.72 % | |||
| Price To Earning | 45.09 X | |||
| Price To Book | 6.10 X | |||
| Price To Sales | 4.39 X | |||
| Revenue | 44.35 B | |||
| Gross Profit | 35.73 B | |||
| EBITDA | 9.09 B | |||
| Net Income | 3.29 B | |||
| Cash And Equivalents | 6.25 B | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 22.96 B | |||
| Debt To Equity | 144.40 % | |||
| Current Ratio | 0.95 X | |||
| Book Value Per Share | 11.95 X | |||
| Cash Flow From Operations | 9.81 B | |||
| Earnings Per Share | 0.99 X | |||
| Price To Earnings To Growth | 1.35 X | |||
| Target Price | 69.28 | |||
| Number Of Employees | 83.5 K | |||
| Beta | 0.19 | |||
| Market Capitalization | 194.57 B | |||
| Total Asset | 96.48 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 4.30 % | |||
| Net Asset | 96.48 B | |||
| Last Dividend Paid | 2.9 |
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.